The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Clinical trial NCT05640726 · UNKNOWN
Trial details
- NCT number
- NCT05640726
- Sponsor
- Fujian Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-01
- Primary completion
- 2024-05-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.